Aug 15th 2013 - Edison Investment Research today published a report on Morphosys entitled "Transformed By Major Alliances". In summary, the report says:
MorphoSys’s recent major licensing deals with GlaxoSmithKline and Celgene mark a transformation of the company. Its main value drivers are now clearly its proprietary products, rather than its broad pipeline of antibodies created for partners. The co-development deal with Celgene also lays down a path for MorphoSys to have eventually its own European oncology sales force. In the meantime, its main focus is on working with its new partners and developing further its proprietary pipeline, possibly through in-licensing products. We value MorphoSys at $1.89bn.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »